Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

2017 ESMO Congress
Tweet this page

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).

Jul

Today In Oncology

FDA Approves Ivosidenib for IDH1-Mutated AML

By Sending Tests by Mail, Researchers Boost Colorectal Cancer Screening Rates Among Medicaid Patients

Study Evaluates Effects of Affordable Care Act on Young Women With Gynecologic Cancer

Prostate-Specific Membrane Antigen–Targeted Docetaxel Nanoparticle in Metastatic Castration-Resistant Prostate Cancer

CALM Psychotherapeutic Intervention Reduces Depression in Patients With Advanced Cancer

;